NCT00360555View on ClinicalTrials.gov

Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

1,584

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions
Sexual Dysfunctions, Psychological
Interventions
DRUG

flibanserin

flibanserin 25 mg b.i.d

DRUG

flibanserin 50mg

flibanserin 50mg qhs/b.i.d.

DRUG

flibanserin 100mg

flibanserin 50 mg b.i.d/100mg qhs

DRUG

placebo

placebo comparator

Trial Locations (77)

Unknown

511.75.01015 Boehringer Ingelheim Investigational Site, Birmingham

511.75.01028 Boehringer Ingelheim Investigational Site, Mobile

511.75.01051 Boehringer Ingelheim Investigational Site, Phoenix

511.75.01063 Boehringer Ingelheim Investigational Site, Little Rock

511.75.01017 Boehringer Ingelheim Investigational Site, Berkeley

511.75.01014 Boehringer Ingelheim Investigational Site, Encinitas

511.75.01042 Boehringer Ingelheim Investigational Site, Fair Oaks

511.75.01022 Boehringer Ingelheim Investigational Site, Irvine

511.75.01005 Boehringer Ingelheim Investigational Site, La Jolla

511.75.01053 Boehringer Ingelheim Investigational Site, Sacremento

511.75.01045 Boehringer Ingelheim Investigational Site, San Diego

511.75.01065 Boehringer Ingelheim Investigational Site, Aurora

511.75.01003 Boehringer Ingelheim Investigational Site, Englewood

511.75.01030 Boehringer Ingelheim Investigational Site, Washington D.C.

511.75.01066 Boehringer Ingelheim Investigational Site, Coral Gables

511.75.01040 Boehringer Ingelheim Investigational Site, Fort Meyers

511.75.01001 Boehringer Ingelheim Investigational Site, Gainesville

511.75.01062 Boehringer Ingelheim Investigational Site, Hollywood

511.75.01032 Boehringer Ingelheim Investigational Site, Ocala

511.75.01047 Boehringer Ingelheim Investigational Site, Orlando

511.75.01073 Boehringer Ingelheim Investigational Site, Palm Bay

511.75.01035 Boehringer Ingelheim Investigational Site, Sarasota

511.75.01010 Boehringer Ingelheim Investigational Site, South Miami

511.75.01041 Boehringer Ingelheim Investigational Site, St. Petersburg

511.75.01033 Boehringer Ingelheim Investigational Site, Tampa

511.75.01002 Boehringer Ingelheim Investigational Site, West Palm Beach

511.75.01006 Boehringer Ingelheim Investigational Site, Sandy Springs

511.75.01023 Boehringer Ingelheim Investigational Site, Chicago

511.75.01031 Boehringer Ingelheim Investigational Site, Fort Wayne

511.75.01050 Boehringer Ingelheim Investigational Site, Lafayette

511.75.01043 Boehringer Ingelheim Investigational Site, Bingham Farms

511.75.01025 Boehringer Ingelheim Investigational Site, Chaska

511.75.01024 Boehringer Ingelheim Investigational Site, Chesterfield

511.75.01009 Boehringer Ingelheim Investigational Site, Kansas City

511.75.01060 Boehringer Ingelheim Investigational Site, Las Vegas

511.75.01004 Boehringer Ingelheim Investigational Site, New Brunswick

511.75.01037 Boehringer Ingelheim Investigational Site, Chapel Hill

511.75.01054 Boehringer Ingelheim Investigational Site, Winston-Salem

511.75.01069 Boehringer Ingelheim Investigational Site, Beachwood

511.75.01012 Boehringer Ingelheim Investigational Site, Cincinnati

511.75.01071 Boehringer Ingelheim Investigational Site, Cincinnati

511.75.01038 Boehringer Ingelheim Investigational Site, Cleveland

511.75.01048 Boehringer Ingelheim Investigational Site, Cleveland

511.75.01061 Boehringer Ingelheim Investigational Site, Columbus

511.75.01020 Boehringer Ingelheim Investigational Site, Tulsa

511.75.01052 Boehringer Ingelheim Investigational Site, Eugene

511.75.01059 Boehringer Ingelheim Investigational Site, Medfod

511.75.01021 Boehringer Ingelheim Investigational Site, Portland

511.75.01018 Boehringer Ingelheim Investigational Site, Jenkintown

511.75.01067 Boehringer Ingelheim Investigational Site, Columbia

511.75.01070 Boehringer Ingelheim Investigational Site, Greenville

511.75.01064 Boehringer Ingelheim Investigational Site, Knoxville

511.75.01049 Boehringer Ingelheim Investigational Site, Nashville

511.75.01013 Boehringer Ingelheim Investigational Site, Austin

511.75.01027 Boehringer Ingelheim Investigational Site, Dallas

511.75.01044 Boehringer Ingelheim Investigational Site, Fort Worth

511.75.01011 Boehringer Ingelheim Investigational Site, Houston

511.75.01055 Boehringer Ingelheim Investigational Site, San Antonio

511.75.01068 Boehringer Ingelheim Investigational Site, Waco

511.75.01007 Boehringer Ingelheim Investigational Site, Charlottesville

511.75.01057 Boehringer Ingelheim Investigational Site, Norfolk

511.75.01046 Boehringer Ingelheim Investigational Site, Richmond

511.75.01019 Boehringer Ingelheim Investigational Site, Seattle

511.75.01036 Boehringer Ingelheim Investigational Site, Middleton

511.75.02008 Boehringer Ingelheim Investigational Site, Coquitlam

511.75.02002 Boehringer Ingelheim Investigational Site, North Vancouver

511.75.02004 Boehringer Ingelheim Investigational Site, Woodstock

511.75.02005 Boehringer Ingelheim Investigational Site, Mount Pearl

511.75.02010 Boehringer Ingelheim Investigational Site, Barrie

511.75.02011 Boehringer Ingelheim Investigational Site, London

511.75.02001 Boehringer Ingelheim Investigational Site, Ottawa

511.75.02007 Boehringer Ingelheim Investigational Site, Toronto

511.75.02012 Boehringer Ingelheim Investigational Site, Québec

511.75.02014 Boehringer Ingelheim Investigational Site, Québec

511.75.02009 Boehringer Ingelheim Investigational Site, Sherbrooke

511.75.02013 Boehringer Ingelheim Investigational Site, Trois-Rivières

511.75.02003 Boehringer Ingelheim Investigational Site, Saskatoon

All Listed Sponsors
lead

Sprout Pharmaceuticals, Inc

INDUSTRY

NCT00360555 - Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder | Biotech Hunter | Biotech Hunter